Inhibition Of Cell Proliferation And Induction Of Differentiation In Human Leukemia K562 Cells By Lidamycin At Low Concentration

Objectives Traditional medicine in the killing of tumor cells at the same time also have serious damage to normal cells.Differentiation of the side effects of treatment method to produce lighter effect is remarkable and is conducive to long-term treatment.Experiments in this paper by low dose lidamycin for chronic granulocyte leukemia K562 cells differentiation of research,explore low dose lidamycin treatment for leukemia.Methods Conventional cultivation of K562 cells,when cells were in the loganthmic growth phase,Application of different concentrations of lidamycin K562 cells 48 h and 72 h.After the treatment cells were collected and subjected to detection and analysis,Trypan blue staining method to detect eed drug effects on cell proliferation,CCK 8 method to detect eed drug effects on cell proliferation.By Wright-Giemsa staining to observe the cell morphology changes,NBT method is put effect on K562 cell differentiation,and detection of hemoglobin content changes,Flow cytometry to detect red blood differentiation of K562 cell surface antigens CD71 surface expression,Western blot detection related transcription factors GATA-1,At different concentrations eed drug induced leukemia cell differentiation.Results Lidamycin on K562 cell proliferation has certain inhibitory effect,The inhibition and drug concentration and action time is related to both.With concentration of 0.001 nmol/L,0.1 nmol/L and 10 nmol/L lidamycin role of K562 cells in 48 h,the inhibitory rates were 26.3±1.5,51.4±1.7 and 70.8±2.4 With concentration of lidamycin role of K562 cells in 72 h,The inhibitory rates were 33.6±1.1,64.2±0.8 and 82.1±1.4.CCK 8 shows that lidamycin role of K562 cells in 48 h,The cell survival rate 97.5±0.32,83.1±0.67,60.3±1.24,50.8±0.85,42.7±1.07,33.2±0.98 and 23.5±1.62,IC50 was 0.1nmol/L.Lidamycin role of K562 cells in 72 h,The cell survival rate 89.5±0.74,71.2±1.31,53.6±1.14,44.8±0.55,34.7±1.74,20.4±1.97 and 12.3±1.43,IC50 was 0.01nmol/L.By Wright-Giemsa staining observed under microscope,control cell morphological rules,equal size,see multiple nucleoli in cells,the experimental group cell body significantly larger,cell size is not equal,part of the nucleus NBT reduction experiment results show that the experimental group were significantly higher(P<0.05).Lidamycin induced after 48 h of hemoglobin content in cells were 0.562±0.116,0.833±0.314 and 0.703±0.204,lidamycin induced after 48 h of hemoglobin content in cells were 0.614±0.33,1.157±0.162 and 0.827±0.174.The cell surface antigens CD71 surface expression after 48 h was 10.1%,16.7%,5.4%.(P<0.05).The cell surface antigens CD71 surface expression after 72 h was 26.3%,71.4%,9.3%.Western blot showed with concentration of 0.001 nmol/L,0.1 nmol/L and 10 nmol/L lidamycin role of K562 cells in 48 h was(2.88±0.15),(4.14±0.17),(3.69±0.08).Western blot showed with concentration of 0.001 nmol/L,0.1 nmol/L and 10 nmol/L lidamycin role of K562 cells in 72 h was(3.07±0.03),(4.87±0.09),(4.26±0.13).The amount of protein expression were raised,(P<0.05).Conclusions 1 Lidamycin has inhibition on human leukemia K562 cells proliferation,and the drug concentration and action time is related to both.2 Lidamycin can induce human leukemia K562 cells differentiation in the direction of red tie.3 Lidamycin can induce human leukemia K562 cells differentiation in the direction of red tie,May be associated with transcription factor GATA-1.